Asset profile

Ruxolitinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — Atopic Dermatitis

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (3)
November 2026 (1)
Phase 2Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm …Recruiting
Est. primary completion 2026-11-11 · NCT04282187 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (2)
Phase 2Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell TransplantationActive not recruiting
Est. primary completion 2026-12 · NCT03286530 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm …Recruiting
Est. primary completion 2026-12-10 · NCT07238712 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (4)
May 2027 (1)
Phase 2Carcinoma, Non-Small-Cell LungActive not recruiting
Est. primary completion 2027-05-31 · NCT06120140 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)
Phase 2/3Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2027-06-01 · NCT07366801 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)
Phase 2Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT02955940 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 1/2Non Small Cell Lung Carcinoma, Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07219576 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
June 2028 (1)
Phase 2AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome) …Recruiting
Est. primary completion 2028-06 · NCT06859424 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
November 2030 (1)
Phase 2Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic SyndromeRecruiting
Est. primary completion 2030-11-22 · NCT06128070 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.